Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.60, read 2026-11-01
Ethical does not pass the values gate
Price125.31 USD
Fair value177.76
Ethical score10.0/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-11-05Read Markup125.31+0.0% to today ✓Markdown gives way to Markup after an 8% rise in 4 days
2026-11-01Read Markdown116.29+7.8% to today Accumulation gives way to Markdown first Markdown read since October
2026-10-25Read Accumulation120.18+4.3% to today ✓Markdown gives way to Accumulation
2026-10-18Read Markdown120.18+4.3% to today Accumulation gives way to Markdown after a 6% rise in 7 days
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Tapestry, Inc. holds its Markup at $125.31. Consolidating, no directional conviction, held for 27 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 27 days
Price at the screen
$125.31
Valuation
16.00 trailing · 13.08 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.43
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
59.25%
Below 33%
Interest-bearing debt is 59.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.30%
Below 33%
Cash held in interest-bearing accounts and securities is 0.3% of assets, under the one-third limit.
Pass
Receivables
20.35%
Below 49%
Money owed to the company is 20.4% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Tapestry,'s business is in a permissible area, but its interest-bearing debt is about 59% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TPR's ethical verdict changes
Today TPR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 30% discount to our $177.76 fair value, narrow competitive moat, 8.90% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 29.5% discount to the base estimate.
Where our models see it going: fair-value estimate $177.76, with a range of $146.64 to $244.40, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Luxury bags hide a balance sheet under strain
Picture a shopper picking up a Coach tote in New York or a Kate Spade satchel in Shanghai. The sale registers, yet the company behind those brands carries debt levels that trip our ethical screen. Tapestry shows solid revenue growth and a high return on equity, but the debt ratio alone rules it out for us.
We pass on this name because the ethical filter exists for exactly these cases. A narrow moat in a cyclical luxury sector adds little comfort when leverage stays elevated. Analyst targets sit near our own fair value, yet none of that overrides the debt concern.
The real exposure sits in consumer spending swings and margin pressure that can appear quickly in downturns. Profit margins remain modest despite the headline growth. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TPR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup · changed$125.31+3.5%Entry 17
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markdown$121.02+4.1%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markdown$116.29+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$116.29+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown · changed$116.29+0.0%Entry 13
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$116.29+5.4%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$110.37+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$110.37-8.2%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165.
2026-10-18Markdown · changed$120.18+5.9%Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 79%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (19 analysts) rates it buy, with a mean price target of $165.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.